Selected ongoing phase III trials utilizing immunotherapy in unresectable disease
| Trial | Stage (AJCC 8th edition) | Treatment | Primary endpoint |
|---|---|---|---|
| KEYLYNK-012 (NCT04380636) | Stage IIIA–C | Pembrolizumab plus CRT followed by pembrolizumab with/without olaparib vs. CRT followed by durvalumab | PFS and OS |
| EA5181 (NCT04092283) | Stage III | Durvalumab plus CRT or CRT, followed by one year of durvalumab | OS |
| Skyscraper-03 (NCT04513925) | Stage III after CRT | Atezolizumab plus tiragolumab or durvalumab | PFS |
| Pacific-9 (NCT05221840) | Stage III after CRT | Durvalumab plus oleclumab or monalizumab or placebo | PFS |
| NCT04325763 | Stage III after CRT | TQB2450 plus anlotinib or TQB2450 or placebo | PFS |
| Pacific-8 (NCT05211895) | PD-L1 positive stage III after CRT | Durvalumab plus either domvanalimab or placebo | PFS |
| NCT04585490 | Stage III after CRT | MRD negative patients after CRT will receive consolidation durvalumab and MRD-positive patients will receive durvalumab plus four additional cycles of tremelimumab chemotherapy | MRD change as measured by ctDNA after tremelimumab chemotherapy |
MRD: minimal residual disease; PD-L1: programmed death 1 ligand; CRT: chemoradiation; ctDNA: circulating tumor DNA; OS: overall survival; PFS: progression-free survival